INIS
antigens
100%
humans
83%
length
58%
antibodies
57%
patients
56%
kidneys
56%
natural killer cells
53%
grafts
51%
genes
42%
tumors
30%
transplants
30%
risks
29%
exons
29%
nucleotides
26%
stem cells
26%
levels
24%
cancer
21%
toxicity
19%
populations
18%
diseases
16%
molecules
16%
failures
16%
receptors
15%
data
15%
rna
14%
surfaces
14%
comparative evaluations
14%
bone marrow
13%
immunotherapy
13%
radiotherapy
13%
therapy
12%
splicing
11%
losses
11%
dna
11%
proteins
11%
mice
10%
assignments
9%
control
9%
ascorbic acid
8%
vitamin c
8%
breasts
8%
leukemia
8%
catalogs
8%
resolution
8%
laboratories
8%
amino acids
8%
solids
8%
blood
8%
in vitro
8%
validation
8%
immunoglobulins
7%
tools
7%
monoclonal antibodies
6%
in vivo
6%
information
6%
screening
6%
peptides
6%
introns
6%
computer codes
6%
reactivity
6%
panels
6%
host
5%
lymphocytes
5%
genotype
5%
nk cells
5%
immunity
5%
evaluation
5%
specificity
5%
hypoxia
5%
tumor cells
5%
chemotherapy
5%
metastases
5%
pregnancy
5%
chains
5%
residues
5%
allocations
5%
messenger-rna
5%
doses
5%
immunosuppression
5%
Keyphrases
Natural Killer Cells
60%
Polymorphism
40%
HLA Antibodies
33%
Human Leukocyte Antigen
27%
Kidney Transplantation
24%
Multiple Myeloma
23%
Epitope
21%
Transplantation
19%
HLA Alleles
18%
Human Leukocyte Antigen Antibodies
18%
Hemizygous
17%
Full-length Sequence
17%
Pretransplant
17%
Graft Survival
15%
Human Leukocyte Antigen Class I
15%
NKG2A
15%
DPB1
14%
Haploidentical Transplantation
14%
Alloreactive
14%
Sanger Sequencing
13%
Radiotherapy
13%
Human Leukocyte antigen-E
13%
Sequence-based Typing
13%
Allele Sequences
13%
Natural Killer
12%
Tumor Microenvironment
12%
Alternative Splicing
12%
Immunogenetics
12%
Bone Marrow
12%
Clinical Significance
11%
Exon 2
11%
PIRCHE
11%
Full-length Gene
11%
New Human Leukocyte Antigen Allele
10%
Multiple Myeloma Patients
10%
HLA-C
10%
Human Leukocyte Antigen Typing
10%
Kidney Graft Survival
10%
Myeloma Cells
10%
High-resolution
10%
DPA1
10%
HLA Class I Molecules
10%
HLA Class I
10%
Natural Killer Cell Cytotoxicity
10%
Non-associated
10%
Coding Sequence
9%
Graft Failure
9%
HLA-DQB1
9%
Killer Cell Immunoglobulin-like Receptor
9%
HLA Matching
9%
Deceased Donor Transplant
9%
Gene Sequencing
9%
Vitamin C
8%
HLA-A*02
8%
Allorecognition
8%
Ascorbic Acid
8%
FCGR3A
8%
HLA-DPB1
8%
HLA-DRA
8%
Allele Frequency
8%
Stem Cell Transplantation
8%
Graft Loss
7%
Myeloma
7%
Sequence Method
7%
Kidney Graft Failure
7%
Expression Level
7%
Allele Groups
7%
MinION
7%
DRB1
7%
DRB3
7%
Alloreactivity
6%
DNA Sequencing
6%
Surface Expression
6%
Buccal Swab
6%
Genome Sequencing
6%
Gene Polymorphism
6%
RNA Sequencing (RNA-seq)
6%
HLA Typing
6%
Antitumor Effect
6%
HLA-A
6%
HLA-B
6%
HLA-E
6%
Human Leukocyte Antigen Genes
6%
Tumor
6%
Human Leukocyte antigen-B
6%
Human Leukocyte antigen-C
6%
Eplet
6%
Kidney Graft
6%
Single nucleotide Polymorphism
6%
HLA-DRB1
5%
Next-generation Sequencing
5%
Rare Allele
5%
Multiplex Bead Assay
5%
Antitumor
5%
Hypoxia
5%
Natural Killer Cell Therapy
5%
Dutch
5%
Healthy Individuals
5%
Differential Effects
5%
Typing Methods
5%
Immunology and Microbiology
Human Leukocyte Antigen
75%
Allele
61%
Natural Killer Cell
60%
Epitope
30%
HLA Antibody
28%
Exon
28%
Multiple Myeloma
27%
Immunology
26%
Kidney Transplantation
24%
Immune Complex
18%
Haplotype
18%
Cytotoxicity
16%
T Cell
16%
Stem Cell Transplantation
15%
Immunotherapy
13%
Vitamin C
13%
Dideoxynucleotide Sequencing
11%
Single Nucleotide Polymorphism
10%
Killer-Cell Immunoglobulin-Like Receptor
9%
Allorecognition
8%
FCGR3A
8%
Alloimmunity
8%
Immunogenetics
8%
Ascorbic Acid
8%
B Cell
8%
Alternative RNA Splicing
8%
Gene Sequence
7%
HLA DRB1 Antigen
7%
Immunity
7%
Interleukin 2
7%
Intron
7%
Cytotoxic T-Cell
7%
RNA Sequence
6%
DNA Polymorphism
6%
HLA DPB1 Antigen
6%
Evolution
6%
Monoclonal Antibody
5%
Graft-Versus-Host Disease
5%
HLA DR Antigen
5%
Cell Surface
5%
Next Generation Sequencing
5%
Multiple Myeloma Cell Line
5%
Alpha Chain
5%
Cell Population
5%
Tumor Cell
5%
DNA Sequence
5%
Cyclophosphamide
5%
Progression Free Survival
5%
CD4
5%
Overall Survival
5%
HLA-DR
5%
Immunoassay
5%